Efficacy and safety of CD19 chimeric antigen receptor T cells in the treatment of 11 patients with relapsed/refractory B-cell lymphoma: a single-center study

BACKGROUND: No effective treatment exist for patients with relapsed and refractory B-cell lymphoma, until the advent of anti-CD19 chimeric antigen receptor (CAR) T-cells. Therefore, this study aimed to explore the factors affecting the efficacy of anti-CD19 CAR T-cell and the adverse reactions of th...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Chen, Wu, Lili, Liu, Ruixia, Li, Weijing, Li, Zheng, Li, Jianqiang, Liu, Lihong, Shan, Baoen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7575989/
https://www.ncbi.nlm.nih.gov/pubmed/33145267
http://dx.doi.org/10.21037/atm-20-4363

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7575989/
https://www.ncbi.nlm.nih.gov/pubmed/33145267
http://dx.doi.org/10.21037/atm-20-4363

Ejemplares similares